Replies to post #23293 on Mymetics Corp (MYMX)

[Work Harder]

Another Themis

?

Better to treat than prevent

Most don't know this but Merck isn't in the allergy or biosimilars market anymore ggggggggg

Prevent is the Mymx insiders motto

LOL

[bow-tie]

Article Escherichia Coli Based Cell Free Protein Synthesis ...
www.mdpi.com/2076-393X/9/3/193/pdf (MERCK)
Vaccines 2021, 9, 193 3 of 28 There are three tandem-core VLPs that are of particular interest to this project (see Figure 2). The first is the tandem-core dimer called the K1K1 VLP which contains a single

Abstract: Tandem-core hepatitis B core antigen (HBcAg) virus-like particles (VLPs), in which two
HBcAg monomers are joined together by a peptide linker, can be used to display two different
antigens on the VLP surface. We produced universal influenza vaccine candidates that use this
scaffold in an Escherichia coli-based cell-free protein synthesis (CFPS) platform. We then used the
CFPS system to rapidly test modifications to the arginine-rich region typically found in wild-type
HBcAg, the peptide linkers around the influenza antigen inserts, and the plasmid vector backbone
to improve titer and quality. Using a minimal plasmid vector backbone designed for CFPS improved
titers by at least 1.4-fold over the original constructs. When the linker lengths for the influenza
inserts were more consistent in length and a greater variety of codons for glycine and serine were
utilized, titers were further increased to over 70 µg/mL (4.0-fold greater than the original construct)
and the presence of lower molecular weight product-related impurities was significantly reduced,
although improvements in particle assembly were not seen. Furthermore, any constructs with the
C-terminal arginine-rich region removed resulted in asymmetric particles of poor quality. This
demonstrates the potential for CFPS as a screening platform for VLPs.
Keywords: Cell-Free Protein Synthesis; Virus-Like Particle; Tandem-Core; Influenza Vaccine

. By expressing tandem-core HBcAg VLPs in our CFPS system and
designing and expressing modified versions of those VLPs, we have demonstrated that
our CFPS system is not only capable of generating complex self-assembling products for
vaccine production, but it is a useful screening tool for the iteration and improvement of
vaccine product design.


Vaccination with virosomally formulated recombinant CyRPA ...
www.nature.com/articles/s41541-020-0158-9
Jan 31, 2020 · Plasmids were amplified by transforming chemically competent Escherichia coli bacteria and used for transfection of human embryonic kidney HEK 293 cells. The histidine-tagged protein was purified ...
https://www.nature.com/articles/s41541-020-0158-9